Yes, dapagliflozin (Farxiga) can be started in this 84-year-old female with an eGFR of 32 mL/min/1.73 m²
Based on the most recent 2022 ADA/KDIGO consensus guidelines, SGLT2 inhibitors with proven kidney or cardiovascular benefit are recommended for patients with type 2 diabetes, CKD, and eGFR ≥20 mL/min/1.73 m² 1. With an eGFR of 32 mL/min/1.73 m², this patient falls well within the recommended initiation range.
Key Evidence Supporting Initiation
The 2022 KDIGO guideline specifically updated the lower eGFR threshold for SGLT2i initiation from ≥30 to ≥20 mL/min/1.73 m², driven by robust trial data including DAPA-CKD 1. Dapagliflozin is FDA-approved for use at 10 mg once daily with eGFR of 25 to <45 mL/min/1.73 m² 1, 2.
The landmark DAPA-CKD trial demonstrated that dapagliflozin significantly reduced the composite risk of sustained eGFR decline ≥50%, end-stage kidney disease, or cardiovascular/renal death (HR 0.61,95% CI 0.51-0.72, p<0.001) in patients with eGFR 25-75 mL/min/1.73 m² 3. Importantly, efficacy and safety were consistent across age groups, including septuagenarians and octogenarians who comprised 25% of participants 4.
Dosing and Monitoring
- Start with dapagliflozin 10 mg once daily 1
- Expect an initial reversible eGFR decline of 3-5 mL/min/1.73 m² within the first 2-4 weeks 5, 6
- Continue therapy even if eGFR drops below 25 mL/min/1.73 m² after initiation, as the drug can be maintained until dialysis 1
- Monitor volume status and renal function after initiation, particularly in elderly patients 2
Critical Risk Mitigation Strategies
Given her age and eGFR, implement these specific precautions:
Volume depletion risk:
- Assess volume status before initiation 2
- Consider proactive diuretic dose reduction if she's on loop diuretics 1, 5
- Monitor for signs of hypotension after starting therapy
Genital mycotic infections:
- Counsel on daily genital hygiene measures 1
- Risk is higher in women (6% vs 1% placebo) 1
- Most infections are easily treated, but monitor for severe cases
Sick day protocol:
- Hold dapagliflozin during acute illness (nausea, vomiting, diarrhea, reduced oral intake) 1, 5
- Resume when clinically stable and oral intake restored
- Educate on ketoacidosis signs (though risk is lower without type 1 diabetes)
Hypoglycemia:
- If on insulin or sulfonylureas, reduce doses to minimize hypoglycemia risk 1
- Maintain at least low-dose insulin if insulin-requiring to prevent ketoacidosis 1
Important Caveats
Do not initiate if:
- eGFR <25 mL/min/1.73 m² per FDA labeling (though guidelines support ≥20) 1, 2
- Polycystic kidney disease or recent immunosuppressive therapy for kidney disease 2
- Active ketoacidosis or severe volume depletion 2
The initial eGFR dip is expected and not a reason to discontinue 1, 5. Both CREDENCE and DAPA-CKD protocols specified continuation when eGFR fell below initiation thresholds 1. The drug provides kidney and cardiovascular protection independent of glucose-lowering effects at this eGFR level 7, 1.
Age alone should not be a barrier - therapeutic nihilism or ageism should not discourage use in octogenarians who are likely to experience considerable benefit from reduced mortality, cardiovascular events, and CKD progression 4.